<DOC>
	<DOCNO>NCT01843647</DOCNO>
	<brief_summary>The purpose study evaluate overall response rate disease free survival IIIAN2 non-small-cell lung cancer patient EGFR 19 21 exon mutation .</brief_summary>
	<brief_title>Neoadjuvant Therapy Icotinib Epidermal Growth Factor Receptor Mutated NSCLC Patients</brief_title>
	<detailed_description>Neoadjuvant therapy use year treat patient non-small-cell lung cancer whose primary tumor large allow surgery . Reduction size primary tumor neoadjuvant therapy make possible patient . Moreover , goal expand include : determination sensitivity tumor subsequent therapy modify accordingly ; prolong disease free survival ; prolong survival .</detailed_description>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Vinorelbine</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Mitogens</mesh_term>
	<criteria>1.The patient sign write informed consent . 2.The patient present operable IIIAN2 nonsmallcell lung cancer 19 21 exon mutation . 3.The patient history anticancer therapy include chemotherapy , radiation therapy , surgical therapy . 4.The patient ' Eastern Cooperative Oncology Group score ≤ 01 . 5.The age patient ≥ 18 year old life expectancy longer 3 month . 1 . Patients unresected tumor . 2 . Wild EGFR type . 3 . Allergic study drug . 4 . Patients severe noncancerous disease . 5 . Patients undergo current administration anticancer therapy , attend clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>December 2014</verification_date>
</DOC>